Article
Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.
British journal of clinical pharmacology - 1 Sept 2014
ter Heine Rob, Binkhorst Lisette, de Graan Anne Joy M, de Bruijn Peter, Beijnen Jos H, Mathijssen Ron H J, Huitema Alwin D R
Abstract excerpt
AIMS: Tamoxifen is considered a pro-drug of its active metabolite endoxifen. The major metabolic enzymes involved in endoxifen formation are CYP2D6 and CYP3A. There is considerable evidence that variability in activity of these enzymes influences endoxifen exposure and thereby may influence the clinical outcome of tamoxifen treatment. We aimed to quantify the impact of metabolic phenotype on the pharmacokinetics...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.